Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population ; day:2 ; month:10 ; year:2023 ; pages:1-7
Prostate cancer and prostatic diseases ; (2.10.2023), 1-7
- Creator
-
Freedland, Stephen J.
Davis, Matthew
Epstein, Andrew J.
Arondekar, Bhakti
Ivanova, Jasmina I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41391-023-00725-8
- URN
-
urn:nbn:de:101:1-2023122515065681468638
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Freedland, Stephen J.
- Davis, Matthew
- Epstein, Andrew J.
- Arondekar, Bhakti
- Ivanova, Jasmina I.
- SpringerLink (Online service)
Other Objects (12)
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
Effect of simvastatin on castration-resistant prostate cancer cells